Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon May 19, 2016 7:09am

119 Views

Post# 24887550

RE:RE:RE:RE:RE:RE:RE:RE:BioWorld-Interesting article

G1945V,

Dont' get excited about seeing "ClinicalTrials.gov processed this record on May 17, 2016" for the Zenith trial. ClinicalTrials.gov lists that for ALL of their trials! Instead, look at the "Last Updated" date, which is April 30, 2016 for the NCT02705469 trial: A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer.

I apologize if you were implying something else from your message and I failed to see it.

BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market